Our Solution


  • SymbiOx has developed a photosynthetic scaffold technology (SymbiO-Derm) that provides physicians with next-generation tools for the treatment, unctional restoration, and healing of damaged or diseased tissues
  • Our products incorporate a three-dimensional photosynthetic matrix that is designed for application directly over acute and chronic skin wounds
  • Exposing the matrix dressing to light produces oxygen, which aids in the ingrowth of healthy tissue, with the potential to close the wound (first prototype or “Basic Platform”). -Additionally, for our second-generation prototype (Molecular Platform), will have the capability to engineer our photosynthetic scaffold to produce wound-healing factors for each of the four stages of the wound healing process: hemostasis, inflammation, proliferation, and remodeling
  • Our prototype has been tested in preclinical settings:
    • Prototype validated (oxygen production in the presence of light)
    • Our basic platform product decreased wound-healing times and improved wound-healing quality
    • Molecular platform showed ability to deliver pro-healing factors
    • No adverse effects were observed after 21 days of exposure
  • More about us

IP Granted

Competitive Advantage

  • SymbiOx’s photosynthetic scaffold technology is the ONLY one that provides oxygen delivery as well as desired pro-regeneration molecules locally to the wound site.
  • With these two novel approaches, oxygen and pro-regeneration molecule delivery at the wound site, our wound healing treatment should accelerate & improve significantly dermal tissue repair, therefore playing an active role in the tissue regeneration process.

In summary our competitive advantages are:

  • Efficacy: Improve the wound healing time closure and quality
  • Safety: Biocompatible (no need for donor typing or matching)
  • Customizable: Engineering of the photosynthetic system to produce specific wound-healing factors required at different phases of the wound healing process
  • Ease of Use: Accomplished with a non-invasive & simple application
  • High Benefit/Cost ratio: Scalable & Reduce treatment-related costs.
  • Biodegradable: No need to be removed from the wound bed
  • Intellectual Property: Technology is backed by US and European patents.

Efficacy and Safety

Systemic effects of implanting photosynthetic biomaterial. Five days post-transplantation no significant differences were detected among the groups in the size of the immune organs (spleen and lymph nodes). The weight loss of the animals did not differ between the two groups. Quantification of immunoglobulins G (IgG) and M (IgM) did not show any variation between the control and SymbioDerm groups. Cytokines C5a, CCL1, CCL12, CD54, M-CSF and TIMP-1 were equally present in the serum of animals regardless the experimental group.